June 27th 2024
Your daily dose of the clinical news you may have missed.
Anticoagulation: Should It Remain Standard Therapy After Cardioembolic Stroke?
September 15th 2007Ischemic infarcts of the brain are usually caused by vascular disease, but 1 in 5 results from emboli that arise in the heart. The largest contributor to cardioembolic stroke is non-valvular atrial fibrillation, which is associated with a 5-fold increased risk of cerebral infarction.
Marginal Benefit for Investigational Venous Thromboembolism Drug
September 12th 2007AMSTERDAM -- Mixed results from trials investigating the clinical efficacy of idraparinux, an investigational long-acting factor X inhibitor, suggest the drug is not as effective as standard therapy for treatment of pulmonary embolism.
Cerebral air embolism resulting from an airplane flight
August 1st 2007The authors describe a case of air embolism that developed during a plane flight in a woman who had a congenital cystic adenomatoid malformation. They review the pathophysiological mechanisms, risk factors, clinical features, and treatment of air embolism.
Oral Anticoagulants Top Antiplatelet Drugs for Stroke Prevention in A-Fib
July 18th 2007ROCHESTER, Minn. -- Patients with nonvalvular atrial fibrillation have about a 33% lower risk of stroke and major vascular events when treated with oral anticoagulants rather than antiplatelet therapy, findings from a systematic review of clinical trials suggest.
Preventing pulmonary embolism with vena caval filters
July 1st 2007* Vena caval interruption has been used in the treatment of deep venous thrombosis (DVT) to prevent PE since the early 1970s. Filter placement has been increasing in the past decade. We estimate that filters are placed in more than 0.2% of all Medicare recipients annually.
Lipoprotein(a): A New Treatment Target?
July 1st 2007Lp(a) is a fascinating variant of low-density lipoprotein (LDL). It is basically an LDL molecule that has been modified by the covalent addition of apoprotein(a). Elevated levels of Lp(a) correlate with increased risk of acute coronary syndromes, cerebrovascular accident, peripheral arterial disease, and coronary mortality. This Q&A session answers some curiosities about Lipoprotein(a).